DDInter1632 DDInter927
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma,
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Salbutamol {u} (Compound) resembles {v} (Compound) Terbutaline
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Salbutamol {u} (Compound) resembles {v} (Compound) Clenbuterol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Levobunolol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Salbutamol {u} (Compound) treats {v} (Disease) asthma
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
Salbutamol {u} (Compound) palliates {v} (Disease) allergic rhinitis
Salbutamol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salbutamol {u} (Compound) causes {v} (Side Effect) Asthenia
Salbutamol (Compound) resembles Terbutaline (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Salbutamol (Compound) resembles Clenbuterol (Compound)
Salbutamol may lead to a major life threatening interaction when taken with Levobunolol
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Salbutamol (Compound) treats asthma (Disease)
Salbutamol (Compound) binds ADRB1 (Gene)
Salbutamol (Compound) palliates allergic rhinitis (Disease)
Salbutamol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salbutamol (Compound) causes Asthenia (Side Effect)